Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Express Scripts
Johnson and Johnson
Julphar
Chinese Patent Office
Mallinckrodt
Chubb
Deloitte
Cerilliant
Federal Trade Commission

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,723,341

« Back to Dashboard

Which drugs does patent 6,723,341 protect, and when does it expire?

Patent 6,723,341 protects MOXATAG and is included in one NDA.

This patent has twenty-six patent family members in five countries.
Summary for Patent: 6,723,341
Title: Antibiotic product, use and formulation thereof
Abstract:An antibiotic product is comprised of at least three dosages forms, each of which has a different release profile, with the C.sub.max for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a C.sub.max at different times.
Inventor(s): Rudnic; Edward M. (N. Potomac, MD), Isbister; James D. (Potomac, MD), Treacy, Jr.; Donald J. (Annapolis, MD), Wassink; Sandra E. (Frederick, MD)
Assignee: Advancis Pharmaceutical Corp. (Germantown, MD)
Application Number:10/325,780
Patent Claim Types:
see list of patent claims
Composition; Dosage form; Use;

Drugs Protected by US Patent 6,723,341

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Vernalis R And D Ltd MOXATAG amoxicillin TABLET, EXTENDED RELEASE;ORAL 050813-001 Jan 23, 2008 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y METHOD OF TREATING TONSILLITIS AND/OR PHARYNGITIS SECONDARY TO STREPTOCOCCUS PYOGENES IN A ONCE-A-DAY AMOXICILLIN PRODUCT ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,723,341

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,667,042 Fluroquinilone antibiotic product, use and formulation thereof ➤ Subscribe
7,074,417 Multiple-delayed release anti-viral product, use and formulation thereof ➤ Subscribe
6,541,014 Antiviral product, use and formulation thereof ➤ Subscribe
6,730,320 Tetracycline antibiotic product, use and formulation thereof ➤ Subscribe
7,282,221 Antiviral product, use and formulation thereof ➤ Subscribe
7,157,095 Multiple-delayed release antifungal product, use and formulation thereof ➤ Subscribe
7,105,174 Multiple-delayed release anti-neoplastic product, use and formulation thereof ➤ Subscribe
7,108,859 Antineoplastic product, use and formulation thereof ➤ Subscribe
8,303,988 Antifungal once-a-day product, use and formulation thereof ➤ Subscribe
6,544,555 Antibiotic product, use and formulation thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,723,341

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2002359768 ➤ Subscribe
Australia 2003257176 ➤ Subscribe
Australia 2003261339 ➤ Subscribe
Australia 2003261359 ➤ Subscribe
Australia 2003262626 ➤ Subscribe
Australia 3983801 ➤ Subscribe
Canada 2400784 ➤ Subscribe
Canada 2470016 ➤ Subscribe
Canada 2494015 ➤ Subscribe
Canada 2494017 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Chubb
Cerilliant
Harvard Business School
Queensland Health
Fuji
QuintilesIMS
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot